U.S. markets closed

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.9200+0.0300 (+1.59%)
At close: 04:00PM EST
1.9200 0.00 (0.00%)
After hours: 07:29PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.8900
Bid1.8800 x 3200
Ask1.9200 x 2200
Day's Range1.8500 - 1.9200
52 Week Range1.8500 - 5.5500
Avg. Volume878,341
Market Cap149.705M
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.8220
Earnings DateMar 03, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for OBSV

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ObsEva SA
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • InvestorPlace

    7 Penny Stocks to Buy for January

    The year 2021 will be remembered for price-action among penny stocks and meme stocks. On a relative basis, the penny stock investing euphoria has declined. However, that does not imply absence of good short- to medium-term money-making opportunities. It’s also nice to start a new year by beating the index or pocketing some quick returns. With the Federal Reserve looking to tighten liquidity, I would not go overboard on penny stocks. There is a possibility of markets remaining jittery. However, i

  • GlobeNewswire

    ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

    Figure 1 Response Rate at 3 Months -Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT

  • GlobeNewswire

    ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference

    GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Monday, January 10, 2022. A webca